MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Azathioprine/6-mercaptopurine

Selected References:

  • Akbari M, et al. 2013. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 19(1):15-22.
  • Alami Z, et al. 2018. Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapie 73(3):199-207.
  • Casanova MJ, et al. 2013. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 108(3):433-40.
  • Christensen LA, et al. 2008. Azathioprine treatment during lactation. Aliment Pharmacol Ther 28(10):1209-13.
  • Davison JM et al. 1985. Maternal azathioprine therapy and depressed haematopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol 92:233-9.
  • de Meij TG, et al. 2013. Dutch Initiative on Crohn and Colitis. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther 38(1):38-43.
  • Dejaco C, et al. 2001. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 121:1048-53.
  • Francella A, et al. 2003. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124(1):9-17.
  • Friedman S, et al. 2017. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: A nationwide cohort study. Reproductive Toxicology 73:196-200.
  • Götestam Skorpen C, et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795-810.
  • Goldstein LH, et al. 2007. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 79(10):696-701.
  • Hoeltzenbein M, et al. 2012. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol 34(3):364-369.
  • Ikram N, at al. 2021. Breastfeeding in women with rheumatic diseases. Lupus Sci Med. 8(1):e000491.
  • Langagergaard V, et al. 2007. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther 25(1):73-81.
  • Matalon ST, et al. 2004. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol 18(2):219-230.
  • Matarazzo L, et al. 2021. Pregnancy outcome in women with childhood onset autoimmune hepatitis and autoimmune sclerosing cholangitis on long-term immunosuppressive treatment. Eur J Obstet Gynecol Reprod Biol. 268:7-11.
  • Moretti ME et al. 2006. Breast-feeding during maternal use of azathioprine. Ann Pharmacother 40(12):2269-72.
  • Motta M, et al. 2007. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am J Perinatol 24(8):441-7.
  • Nørgård B, et al. 2004. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 19(6):679-685.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.